Europe’s biggest firm, whose sales of Wegovy almost doubled, feels it can ‘meet demands’ of US administration

Europe’s biggest company, Novo Nordisk, has rebuffed fears of a hit to its business from Donald Trump’s threatened tariffs, as it reported better-than-expected revenues after sales of its weight-loss drug Wegovy almost doubled.

Since taking office, the US president has imposed tariffs on Mexico and Canada – since paused for a month – and China, and has said levies of imports from the EU will “definitely happen”.